- Home
- GLUE vs HCSG Comparison
GLUE vs HCSG Comparison
Compare GLUE & HCSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | HCSG |
|---|---|---|
| Founded | 2019 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Assisted Living Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GLUE | HCSG |
|---|---|---|
| Price | $13.81 | $21.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $32.00 | $22.67 |
| AVG Volume (30 Days) | ★ 948.5K | 631.3K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.83 |
| EPS | N/A | ★ 0.69 |
| Revenue | $123,672,000.00 | ★ $1,837,173,000.00 |
| Revenue This Year | N/A | $7.39 |
| Revenue Next Year | $2.45 | $5.22 |
| P/E Ratio | $72.42 | ★ $31.68 |
| Revenue Growth | ★ 63.54 | 7.08 |
| 52 Week Low | $6.07 | $15.26 |
| 52 Week High | $25.77 | $25.75 |
Technical Indicators
Market Signals| Indicator | GLUE | HCSG |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 41.88 |
| Support Level | N/A | $20.92 |
| Resistance Level | $16.66 | $22.83 |
| Average True Range (ATR) | 0.78 | 0.60 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 38.90 | 21.83 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About HCSG Healthcare Services Group Inc.
Healthcare Services Group Inc is a provider of housekeeping and facility management services to the healthcare industry. The company manages and evaluates its operations in two reportable segments: Environmental Services segment includes housekeeping, management of clients' housekeeping departments, cleaning, disinfecting and sanitizing, laundry, bed linen, and uniform services, linen and other services; and Dietary Segment includes dietary department services, food purchasing, meal preparation, and providing dietitian consulting services. Its clients are nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States of America. The Environmental Services segment derives maximum revenue.